Solid Tumor Targeting CAR-T Development Service: Repolarizing MDSC & TAM

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service provides an advanced solution for overcoming the immunosuppressive tumor microenvironment through Myeloid-Derived Suppressor Cells (MDSCs) and Tumor-Associated Macrophages (TAMs) repolarization. Featuring next-generation CAR-T engineering, immune reprogramming strategies, and translational process optimization, this service enhances therapeutic precision and efficacy while accelerating clinical readiness. By integrating immune modulation with robust manufacturing design, it enables researchers to unlock the full potential of CAR-T therapy in solid tumors.

Introduction

The immunosuppressive TME severely limits the efficacy of CAR-T therapy against solid tumors. A major hurdle is the presence of MDSCs and TAMs, which act as the tumor's "protective shield" by inducing T-cell exhaustion, depleting nutrients, and secreting inhibitory cytokines (TGF-β and IL-10). Next-generation strategies, including MDSC/TAM repolarization and intrinsic CAR-T armoring, are essential to dismantle these barriers, enhance T-cell infiltration, and ensure durable anti-tumor activity.

Creative Biolabs' Service

At Creative Biolabs, we deliver comprehensive and cutting-edge solutions to break through the formidable barriers of the solid tumor microenvironment. Our next-generation CAR-T engineering platforms are designed to endow T cells with superior adaptability, persistence, and anti-tumor potency. By integrating cell-intrinsic resistance mechanisms, our CAR-T cells can withstand metabolic deprivation, oxidative stress, and inhibitory cytokines. Simultaneously, our TME reprogramming strategies actively reshape the immunosuppressive milieu by eliminating MDSCs, repolarizing TAMs toward an M1-like phenotype, and restoring effector immune activation. Leveraging advanced gene-editing, cytokine-arming, co-stimulatory optimization, and chemokine receptor modulation, we create multi-functional CAR-T cells capable of both enduring and remodeling the TME.

Discover How We Can Help - Request a Consultation.

What We Can Offer

• MDSC/TAM Depletion & Repolarization: We design dual-targeting CAR constructs incorporating scFvs such as anti-TR2 or anti-CD33 to selectively eliminate MDSCs and reprogram TAMs from an M2 to an M1 phenotype, reshaping the immune landscape toward tumor clearance.
• Cytokine Signal Resistance: By introducing Dominant-Negative Receptors, our CAR-T cells resist key inhibitory pathways that drive exhaustion, maintaining robust function and persistence even in fibrotic, suppressive tumors.
• Enhanced Infiltration & Penetration: To improve tumor access, we equip CAR-T cells with chemokine receptors and enzymes to degrade extracellular matrix barriers, enabling deep intra-tumoral trafficking and infiltration.

Our Workflow

Core Benefits

• Multi-Modal Engineering Expertise: Our specialized portfolio integrates proven TME-targeting modules: cytokine DNRs, MDSC-depleting receptors, and ECM-degrading enzymes to overcome multiple resistance barriers.
• High-Throughput TME Target Library: Access our proprietary library of pre-validated TME targets for rapid screening and lead identification tailored to your tumor type.
• Compliance and Translational Focus: All constructs and protocols are designed for manufacturing, leveraging published data and validated platforms to ensure seamless clinical translation.

FAQs

Partner with Us

Creative Biolabs is dedicated to transforming the solid tumor landscape by overcoming the TME. Our Solid Tumor Targeting CAR-T Development Service: Repolarizing MDSC & TAM provides the scientific rigor, engineering expertise, and translational focus required to advance your most challenging oncology candidates. From TME immune profiling to dual-targeting CAR design, we offer a high-value, streamlined pathway to next-generation cell therapies. Contact Our Team for More Information and to Discuss Your Project.